AZD7442 prophylaxis trial met primary endpoint
20 August 2021 07:00 BST AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19 77% reduced risk of developing symptomatic COVID-19 First long-acting antibody combination to prevent COVID-19 Positive high-level results from the PROVENT Phase III pre-exposure prophylaxis trial showed AstraZeneca's AZD7442 achieved a statistically significant reduction in the incidence of symptomatic COVID-19, the trial's primary endpoint. AZD7442, a combination of two long-acting antibodies (LAAB), reduced the risk of developing symptomatic COVID-19 by